Fluoxetine once every third day in the treatment of major depressive disorder

European Archives of Psychiatry and Clinical Neuroscience

Volumn 253, Issue 6, 2003, Pages 307-312

  Tural, Ümit ^a   Onder, Emin ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Depression; Fluoxetine; Interrupted dosing; Less frequent dosing; Once every third day

Indexed keywords

FLUOXETINE; NORFLUOXETINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RESTLESSNESS; SEXUAL DYSFUNCTION; SURVIVAL; TREMOR; VOMITING;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEMOGRAPHY; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOXETINE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0347285505     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-003-0445-2     Document Type: Article

References (24)

1. Altamura AC, Montgomery SA (1990) Fluoxetine dose, pharmacokinetics and clinical efficacy. Rev Contemp Pharmacother 1:75-81
2. Altamura AC, Montgomery SA, Wernicke JF (1988) The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 153 (suppl. 3):109-112
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DC
4. Buongiorno PA, Plewes JM, Wilson MG (2002) Cohort experience in 39 psychiatric outpatients with high doses of an entericcoated weekly formulation of fluoxetine. Clin Drug Invest 22:173-179
5. Burke WJ, Hendricks SE, McArthur-Miller D, Jacques D, Bessette D, McKillup T, Stull T, Wilson J (2000) Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol 20:423-427
6. Burke WJ, McArthur-Miller DA (2001) Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. J Clin Psychiatry 62 (Suppl. 22):38-42
7. Claxton A, de Klerk E, Parry M, Robinson JM, Schmidt ME (2000) Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 61:928-932
8. Emmanuel NP, Ware MR, Brawman-Mintzer O, Ballenger JC, Lydiard RB (1999) Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry 60:299-301
9. rd (1987) A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 48:406-408
10. First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured clinical interview for DSM-IV axis I disorders (SCID). Clinical version. American Psychiatric Press, Washington DC
11. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296
12. Hiemke C, Härtter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11-28
13. Kabinoff GS, Plewes JM, Wilson MG (2002) Weekly formulation of fluoxetine for newly treated patients with depression. Clin Drug Invest 22:403-405
14. Linden M, Osterheider M, Nickelsen T, Schaaf B (1993) Three types of early termination of antidepressant drug treatment. Int Clin Psychopharmacol 8:345-346
15. Megna JL, Devitt PJ (2001) Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania. Ann Pharmacother 35:45-47
16. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K (1998) The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55:1128-1132
17. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M (2002) Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomised, double-blind, placebo-controlled clinical trial. Clin Ther 24:417-433
18. Montgomery SA, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D (1990) Plasma-level response relationships with fluoxeine and zimelidine. Clin Neuropharmacol 13 (Suppl 1): S71-S75
19. National Institutes of Mental Health (1976) Clinical Global Impression Severity Scale. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. US. Government Printing Office, Washington DC
20. Rickels K, Smith WT, Glaudin V, Amsterdam JB, Weise C, Settle GP (1985) Comparison of two dosage regimens of fluoxetine in major depression. J Clin Psychiatry 46:38-41
21. Schmidt ME, Fava M, Robinson JM, Judge R (2000) The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 61:851-857
22. Tollefson GD (1995) Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB (eds) Textbook of Psychopharmacology. American Psychiatric Press, Washington DC, pp 161-182
23. Wernicke JF, Bosomworth JC, Ashbrook E (1989) Fluoxetine at 20mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol 4 (Suppl. 1): 63-67
24. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M (1988) Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24:183-188